Lee, Eric Hee Jun
Murad, John P. http://orcid.org/0000-0003-0637-2414
Christian, Lea
Gibson, Jackson
Yamaguchi, Yukiko
Cullen, Cody
Gumber, Diana
Park, Anthony K.
Young, Cari
Monroy, Isabel
Yang, Jason
Stern, Lawrence A.
Adkins, Lauren N.
Dhapola, Gaurav
Gittins, Brenna http://orcid.org/0000-0003-2457-9515
Chang, Wen-Chung
Martinez, Catalina
Woo, Yanghee http://orcid.org/0000-0002-6676-0593
Cristea, Mihaela
Rodriguez-Rodriguez, Lorna
Ishihara, Jun http://orcid.org/0000-0002-9083-9859
Lee, John K. http://orcid.org/0000-0002-6570-2180
Forman, Stephen J. http://orcid.org/0000-0002-2803-4152
Wang, Leo D. http://orcid.org/0000-0002-2945-9005
Priceman, Saul J. http://orcid.org/0000-0002-8136-2112
Funding for this research was provided by:
California Institute for Regenerative Medicine (DISC-11107)
Article History
Received: 7 July 2022
Accepted: 13 July 2023
First Online: 7 August 2023
Competing interests
: S.J.P. and S.J.F. are scientific advisors to and receive royalties from Mustang Bio. S.J.P. is also a scientific advisor and/or receives royalties from Imugene Ltd, Bayer, Adicet Bio, and Celularity. S.J.P., E.H.L., J.P.M., and S.J.F. are listed as co-inventors on a patent on the development of TAG72-targeted CAR-modified T cells for the treatment of TAG72-positive tumors, and S.J.P., E.H.L., and J.P.M. are listed as co-inventors on a patent on the development of membrane-bound IL12 engineered CAR T cells for the treatment of cancer, which are owned by the City of Hope. All other authors declare that they have no competing interests.